This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Molecular biology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Wilms' tumour gene (WT1) is a tumour suppressor which resides at chromosome 11p13. The protein encoded by the WT1 gene is a transcriptional repressor that downregulates expression of the insulin-like growth factor II and the insulin-like growth factor I receptor.

Differential splicing of the WT1 transcript results in four isoforms of the final protein.

All isoforms have four zinc finger DNA-binding domains but they have differing sequence specificities.

WT1 is expressed in:

  • nephrogenesis - in the condensed mesenchyme, renal vesicle and glomerular epithelium
  • the indifferent gonad, eventually being restricted to the Sertoli cells of the testis and granulosa and epithelial cells of the ovary, and the uterus
  • WT1 is also one of the molecules that are known to control cellular apoptosis (3)

Reference:

  • Breuning, W. et al.. Nature Genetics1992; 1: 144-8
  • Skuse GR, Ludlow JW. Tumour suppressor genes in disease and therapy. Lancet 1995;345: 902-6.
  • Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007;21: 868-876.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.